Key Takeaways

  • Humana (NYSE:HUM) increased 14.82% in premarket activity on October 9, 2026 on a displayed price of USD 387.12, extending a rally that began when CMS released its 2027 star ratings.
  • The principal catalyst is a ratings upgrade: Humana's largest Medicare Advantage contract moved to 4 stars from 3.5 stars, restoring eligibility for federal quality Bonus payments.
  • The financial benefit is delayed. Reports say the bonus effect indicates up mainly in 2028 revenue, because ratings released now drive payments for a later plan year.
  • Rival Alignment Healthcare moved the other way, falling approximately 23% premarket after its largest California contract slipped to 3.5 stars from 4, so ratings cut both ways.

Factors Behind Humana’s Share-Price Move

Humana (NYSE:HUM) was indicated to be up 14.82% in the October 9, 2026 premarket session, grounded in a quoted price of USD 387.12 on the premarket screener. Released reports tie the move to the Centers for Medicare and Medicaid Services 2027 Star Ratings, released on October 8, 2026, in which the insurer's largest Medicare Advantage contract increased to 4 stars from 3.5 stars. Reports also characterized a gain of approximately 16.5% in the October 8 session, so the premarket figure and the daily figure overlap in time and should not be added together. Another premarket quote demonstrated a smaller gain approximately 13.4%, which demonstrates how fast indicated prices shift before the open. Every move here is a premarket or disclosed quote, not a closing price.

How Star Ratings Drive Revenue

CMS rates Medicare Advantage contracts from 1 to 5 stars using clinical outcomes, member experience and plan operations. Contracts rated 4 stars or higher qualify for quality bonus payments, which raise the federal funding an insurer receives per member. This makes a half-star move around the 4 star line unusually valuable: Humana (NYSE:HUM) regained eligibility on its biggest contract, while Alignment lost it on its biggest. Humana's own history demonstrates the stakes. After its 2024 ratings declined, the share of members in plans rated 4 stars or better declined from 94% to 25% for the following year, according to a released account. Bonus payments tied to the new ratings are disclosed to flow mainly into 2028.

Principal Risks and Upcoming Developments

The upgrade restores eligibility but does not guarantee earnings, and a rally of this size prices in a lot. Humana (NYSE:HUM) still confronts medical cost trends, risk adjustment changes and annual rate notices that decide margins long before 2028 bonus dollars arrive. Investors may wish to read the full contract-level ratings, since one substantial contract does not define the whole book, and watch the next Quarterly Report for cost commentary. Alignment Healthcare demonstrates how concentrated membership magnifies a single rating decision. Volume during premarket trading was thin, 1,945 shares at the screener snapshot, so the indicated price can swing sharply at the open and should not be read as a settled valuation.

Current Assessment

Humana (NYSE:HUM) has advanced in premarket because CMS lifted its largest Medicare Advantage contract to 4 stars from 3.5 stars, restoring eligibility for quality bonus payments, according to released reports on the October 8 ratings statement. That is a real catalyst, but the payoff is mostly a 2028 story, and the stock had already risen approximately 16.5% on October 8. The balance of supporting information points to better Earnings power, tempered by cost trends and the possibility that much of the potential benefit is priced in. The next items to monitor are the contract-level ratings detail and the next earnings report.